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Background: Over recent decades there has been a substantial increase in asthma and allergic disease especially in
children. Given the high prevalence, and the associated high disease burden and costs, there is a need to identify
effective strategies for the primary prevention of asthma and allergy. A recent systematic review of the literature
found strong supportive epidemiological evidence for a protective role of the Mediterranean diet, which now
needs to be confirmed through formal experimental studies. This pilot trial in pregnant women aims to establish
recruitment, retention and acceptability of a dietary intervention, and to assess the likely impact of the intervention
on adherence to a Mediterranean diet during pregnancy.
Methods/Design: This study was a pilot, two-arm, randomised controlled trial in a sample population of pregnant
women at high risk of having a child who will develop asthma or allergic disease.
Discussion: The work ultimately aims to contribute to improving health outcomes through seeking to reduce the
incidence of asthma and allergic problems. This pilot trial will prove invaluable in informing the subsequent
planned large-scale, parallel group, randomised controlled trial.
Trial registration: ClinicalTrials.gov: NCT01634516
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In recent decades, there has been a marked worldwide
increase in asthma and allergic disease prevalence, especially
in children [1,2]. Children bear the greatest burden of
asthma and allergic disease, principally atopic dermatitis/
eczema, allergic rhino-conjunctivitis and food allergy [3].
Asthma is a major public health concern – the World
Health Organization estimates that globally 235 million
people currently have asthma and that it is now one of the* Correspondence: d.a.sewell@hw.ac.uk
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reproduction in any medium, provided the ormost common childhood diseases requiring chronic drug
therapy [4].
Estimates state that in the UK 1.1 million children and
4.1 million adults receive treatment for asthma. The cost
of asthma for the UK economy was estimated to be £2.3
billion in 2001, comprising £1.2 billion in lost productivity
and £889 million in National Health Service (NHS)
expenditure [5,6]. The UK prevalence of atopic dermatitis/
eczema and hay fever in children is also high, such that
internationally the UK was ranked second for prevalence
of atopic dermatitis/eczema and seventh for hay fever [7,8].
In Scotland in 2004, nearly 4% of general practitioner
consultations and 1.5% of hospital admissions were for
allergic disorders [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and early-life exposures influence the development of
asthma and allergic diseases, with interest converging on
the possible role of the diet during pregnancy and early
life. It has been hypothesised that the maternal diet during
pregnancy modulates the development of asthma and
allergic disease by influencing foetal airway and/or immune
development [10]. Birth cohort studies have reported
associations between aspects of maternal diet during
pregnancy and childhood asthma and allergic outcomes
[11]. A recent systematic review and meta-analysis exam-
ined the strength of the scientific evidence for associations
between dietary intake of foods and nutrients by pregnant
women and children, and the risk of children developing
asthma and other allergic disorders [12]. Of nearly 15,000
potentially relevant articles, 62 satisfied the inclusion
criteria. There were no randomised controlled trials
(RCTs); all were cohort, case–control or cross-sectional
studies. Although these study designs are potentially at
high risk of bias in assessing the effectiveness of dietary
constituents/patterns, the review results found a poten-
tially substantial protective role for vitamins A, D and
E, zinc, fruit and vegetables, and a Mediterranean diet
(MD) for the prevention of asthma and allergic disorders.
Of these dietary candidates, vitamin D [13] and vitamin E
[14] are under investigation. In general, the MD is
characterised by the elevated intake of fruits and vegetables,
olive oil, legumes, nuts and fish [15]. The study of dietary
patterns represents a broader picture of food and nutrient
consumption compared with single food items and
nutrients [16,17].
Of the five observational MD studies in the review, one
used a cohort design [16] and four were cross-sectional
studies [18-21]. The higher quality cohort study reviewed
by Nurmatov and colleagues [12] reported that high
adherence to a MD was found to be protective against
persistent wheeze (odds ratio = 0.22, 95% confidence
interval = 0.08, 0.58), atopic wheeze (odds ratio = 0.30,
95% confidence interval = 0.10, 0.90) and atopy (odds
ratio = 0.55, 95% confidence interval = 0.31, 0.97) [16].
There are large geographical differences in the prevalence
of asthma, with higher prevalence rates in English-speaking
countries and lower prevalence rates in, for example, the
Mediterranean region [22,23]. As a result of a high intake
of olive oil, vegetables and fruit, wholegrain cereals and
bread, a low intake of dairy products, some fish consump-
tion, and only small amounts of red meat, a MD is rich in
antioxidants but also high in carbohydrates, fibre and
unsaturated fatty acids and low in saturated fatty acids.
Whilst observational studies have reported potentially
beneficial associations with a MD, it is not known
whether an intervention to promote the MD reduces the
likelihood of childhood asthma and allergic disease.
There are currently no RCTs testing the hypothesis thata MD decreases the risk of asthma and allergic disease
in children. Before testing this hypothesis in a large-scale
RCT, pilot work is needed to ensure there is a robust
measure to assess the MD and to investigate the feasibility
of achieving and sustaining a dietary change. We are
carrying out a pilot trial of an intervention to promote a
MD, to inform a subsequent multi-centre RCT. We
report here the protocol for the pilot trial in a sample of
pregnant women.Aims of the study
The primary aims of the pilot trial are to investigate rates
of maternal recruitment and retention in the control and
intervention groups, and to assess the acceptability of
dietary advice and dietary modifications in the intervention
group.
The secondary aims are to determine whether there
are measurable changes in the MD score in both groups,
and to measure adherence to a MD during the last trimester
of pregnancy in the intervention group.Specific research questions
The research questions are as follows: What are the
recruitment and retention rates of pregnant mothers
whose infants are at high risk of asthma/allergy? To
what extent do mothers adhere to a MD? Can a MD
score be increased in pregnancy? Can any increases in
MD adherence be sustained during pregnancy? Can a
measurable change in a biomarker of oxidative stress be
detected as a result of adherence to a MD? Is the advice
and dietary modification acceptable to participants? To
inform cost-effectiveness considerations, can a breakdown
of intervention delivery time (initial contact and number
and duration of follow-up telephone calls) be measured?Methods/Design
Ethical and research and development approval
A favourable ethical opinion was obtained from the NHS
Lothian South East Scotland Research Ethics Committee
02 on 12 April 2012 (REC reference 12/SS/0052). NHS
Lothian R&D Management Approval was obtained on 27
April 2012 (R&D No. 2012/SJ/DN/01).Trial design
We are carrying out a two-arm, pilot, parallel-group RCT.
Trial participants are being recruited from two maternity
service sites in Scotland, both with dating scan appoint-
ment rates of approximately 100 per month. Eligible
participants receive either: diet advice and support, with a
supporting MD resource booklet, in addition to standard
care; or standard care with no additional dietary advice/
support/materials.
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Inclusion criteria
The inclusion criteria are as follows: pregnant in first tri-
mester; age ≥16 years; a history of atopic dermatitis/eczema,
food allergy, allergic rhinitis (persistent or intermittent) or
asthma in the pregnant woman, her partner, or children;
and willing to give informed consent.
Exclusion criteria
The exclusion criteria are as follows: not pregnant;
age <16 years; no history of atopic dermatitis/eczema,
food allergy, allergic rhinitis (persistent or intermittent) or
asthma in the pregnant woman, her partner, or children;
recent (within the last 3 months) or current involvement
in a dietary or supplementation trial; and unable/unwilling
to give informed consent.
Recruitment
Hospital/community treatment centre
We have recruited one hospital and one community treat-
ment centre in the same NHS Scotland Board/region that
carry out dating scans.
Participants
A letter of invitation to join the pilot trial, information
for participants and a consent form are being sent out to
women along with their dating ultrasound scan appoint-
ment letter and pack. These are sent by a health records
department running a centralised regional telephone
booking system and booking clerks are keeping a record
of invitations sent. Interested participants are invited to
contact the researcher by text, telephone or email to
discuss the trial. They are then screened for eligibility to
take part in the trial. Eligibility of women at high
asthma/allergic risk for the foetus is based on a positive
answer to the question: ‘Do you (the mother), or the
father, or sibling of the baby have an allergic disease:
eczema, a food allergy, hay fever or asthma?’ Details are
recorded on the screening questionnaire.
Enrolled participants are sent a food frequency question-
naire (FFQ; Scottish Collaborative Group Food Frequency
Questionnaire version 6.6) for completion at home and a
small urine collection vessel with instructions to fill the
container on the day of the scan and bring that, the
consent form and the completed FFQ to their ultrasound
scan appointment. The researcher then arranges to meet
the participant in the clinic waiting area after their dating
scan, where the researcher collects the consent form,
urine sample and FFQ and administers a baseline MD
questionnaire (based on [18]). Urine specimens are being
stored frozen at −80°C for subsequent analysis.
There are two further opportunities for recruitment.
First, following invitation, when nonresponders arrive in
the clinic they may see a poster in the clinic advertisingthe study. If they would like to take part they can ask
the clinic staff to point out the researcher to them. If the
potential participant has already read the information
for participants then they are able to consent and can be
recruited after the dating scan that day. Second, those
who are interested, but have not read the information
for participants are given a further period of time
(that is, ≥24 hours) before being contacted by the re-
searcher to see whether they wish to participate; if recruited
and randomised to the intervention group, the participant
is asked to return to the hospital for the intervention or
alternatively the researcher can arrange a home visit.
Consent is obtained to inform the participants’ general
practitioner of her participation in the trial, and a letter
is subsequently sent to the general practitioner.
Randomisation
Participating women are randomised when visiting the
hospital for their dating ultrasound scan. Allocation to the
intervention arm or control arm is by restricted random-
isation (by site), via pre-randomised sealed envelopes,
based on a predetermined random number allocation.
This randomisation has been carried out by an independent
statistician. Participants are randomised after consent has
been obtained and immediately after the first MD ques-
tionnaire has been completed. Participants are enrolled
for a total of ~6 months (that is, from 12 to 36 weeks of
pregnancy).
Intervention
The intervention is a 15-minute structured dietary advice
session encouraging the consumption of particular foods
that are consistent with the MD, developed with a
dietitian and administered by a researcher or hospital
dietitian using a booklet. The initial session is directed at
increasing consumption of MD foods, with subsequent
supportive telephone calls from the dietitian/researcher at
4, 8 and 18 weeks post enrolment, to review and revise
MD goals. The booklet contains text and pictures, with
frequently asked questions and answers and ideas for
modifying the diet, such as eating more fruit, vegetables,
using olive oil and eating more fish. Advice for cutting
back on fat on meat is also included. A MD pyramid
(adapted from [24]) is contained in the booklet and
discussed. The dietitian/researcher also discusses ideas
for participants to reach the goals of eating more fruit,
vegetables and fish in the context of current portion
consumption, and reducing red and processed meat by
exchanging with white meat. The use of olive oil for
cooking and dressings is encouraged, and participants
are given a shopping voucher (£10) at baseline and
12 weeks post baseline that can be used for purchasing
olive oil. Olive oil used for cooking and dressings is an
important component of the MD. The MD booklet also
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all of which have olive oil as an ingredient. No energy
restrictions are suggested, and the target of at least five
portions of fruit and vegetables per day is emphasised.
Intervention arm
After the dating scan the researcher collects the consent
form, the FFQ and the urine sample and checks that the
participant has previously received standard dietary advice
for pregnant women, including the importance of folic
acid and vitamin D supplementation. Participants then
receive a 15-minute dietary advice session. A supermarket
voucher to the value of £10 is provided.
At 12 weeks post-baseline, a second MD questionnaire
with a reply envelope for completion and return is
posted to the participant and followed up by a telephone
call from the researcher. A further supermarket voucher
to the value of £10 is sent to the participant on receipt of
the completed questionnaire, accompanied by advice to use
it to buy olive oil. Non-returns of diet questionnaires are
followed up by a telephone enquiry from the researcher
after 1 week, with a reminder letter and another question-
naire being sent out after 2 weeks without a response.
Two weeks before the 24 weeks post-baseline MD
questionnaire, participants are contacted by telephone to
arrange a home visit and are sent a second FFQ. When
visited at home by the researcher, a third MD question-
naire and second FFQ and a urine sample are collected.
Free telephone access to the researcher is available
throughout the study; the frequency and duration of
calls to the researcher are being recorded.
Control arm
After the dating scan the researcher collects the consent
form, the FFQ and the urine sample and checks that the
participant has previously received standard dietary advice
for pregnant women, including the importance of folic acid
and vitamin D supplementation. These participants do not
receive the 15-minute dietary advice session. A supermar-
ket voucher to the value of £10 is provided. The first
follow-up by the researcher is by telephone 12 weeks post-
baseline to inform them they will receive the second MD
questionnaire and reply envelope for completion and
return. A further supermarket voucher to the value of £10
is sent to the participant on receipt of the completed ques-
tionnaire. Non-returns of diet questionnaires are followed
up by a telephone enquiry from the researcher after 1 week,
with a reminder letter and another copy of the question-
naire being sent out after 2 weeks without a response.
Two weeks before the 24 weeks post-baseline MD
questionnaire, participants are contacted by telephone to
arrange a home visit and are sent a second FFQ. When
visited at home by the researcher, a third MD question-
naire and second FFQ and a urine sample are collected.Assessment of outcomes
Recruitment and retention
The number of women who received an invitation,
responded, were eligible, were recruited and completed
the trial will be recorded.
Measuring the Mediterranean diet score
The MD score is being measured at baseline (around
12 weeks of pregnancy) and at 12 and 24 weeks post
baseline MD questionnaire (i.e. approximately weeks 24
and 36 of pregnancy). The number of times participants
consume particular food groups in the last week is
classified into never, one or two times, or three or
more times. For beneficial components (for example,
vegetables, legumes, fruits, cereals, fish, dairy products)
the frequency scoring is higher than for components
considered less beneficial (meat, fast food, confectionery).
As our trial involves pregnant women, we assume dairy
products to be protective and we will not include alcohol
consumption in the score [16]. This is because of the
increased requirement for calcium and the fact that
alcohol consumption is not recommended in pregnancy.
A 3-point increase in MD score on a scale of 22 could
equate to potentially moving from a low-quality maternal
MD score into the optimal range of MD score based on
the study of Chatzi and colleagues [16].
Biomarker analysis
Urine samples are being collected from participants at
baseline and 24 weeks post intervention. We will measure
levels of urinary 8-hydroxy-2′-deoxyguanosine, the ratio
of nitrite to nitrate, and ferric-reducing antioxidant power.
Urinary 8-hydroxy-2′-deoxyguanosine is a sensitive, stable
and integral marker of oxidative stress in vivo [25]. The
stable metabolic products of nitrous oxide and nitrite/
nitrate are markers of whole-body nitrous oxide production.
Total antioxidant activity is measured by the ferric-
reducing antioxidant power. These analytes will be
used as outcome measures in order to relate changes in
oxidative stress, activity and nitrous oxide production to
changes in MD score.
Food frequency questionnaire
FFQ estimates of nutrient intake will be used to support
the MD score and to compare the intervention and control
groups.
Qualitative evaluation of the trial
A sample of participants will be contacted by telephone at
the end of the trial period for a recorded semi-structured
telephone interview by one of the researchers not involved
in meeting the participants. The sample will be weighted
2:1 in favour of the intervention group. This interview will
address participants’ views regarding the acceptability of
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the trial.
Health economics
We are recording the time taken to deliver the intervention,
and the frequency and duration of follow-up telephone
calls, to assess the feasibility of reporting intervention
costs in a subsequent large-scale RCT. Any problems
arising in recording this information will be reported. The
patterns of researcher/dietitian time usage in the pilot
trial will be used to inform the design of the proposed
subsequent RCT.
Measurement of potential confounders
We are collecting data related to potential confounders
such as the baby’s birth weight, sex, socioeconomic status,
maternal education level and exposure to smoking during
pregnancy. Given the small sample size in this pilot trial,
there will be a limit to how many confounders it will be
possible to adjust for in the analysis; however, we will be
able to describe their distribution in the two groups.
Sample size
Our intention is to continue recruitment until we have
50 women included in the trial in order to answer our
research questions. Both centres have approximately 100
dating scans per month, but there is seasonal variation.
We estimate that at least 800 invitations will be made, and
those who do not respond prior to the ultrasound scan
appointment have a further opportunity to take part if
they respond to the clinic poster. Of the 800+ invitations
made, we estimate that one-quarter (n = 200) will fulfil the
eligibility criteria (‘Do you (the mother), or the father, or
sibling of the baby have an allergic disease …?’). This
estimate is based on an overall assessment of the
epidemiology of allergic disorders in Scotland, systematic
reviews of a number of previous primary prevention trials
[26,27] and a recent dietary intervention trial in pregnant
women [14]. Based on our discussions with consumer rep-
resentatives that have informed this pilot trial, we antici-
pate that ~25% (that is, n = 50) of eligible women will be
willing to take part and, with an estimated 20% attrition/
incomplete data collection during the course of the
pregnancy, we anticipate that 40 participants will
complete the study. If these assumptions are fulfilled,
recruitment and retention will be comparable with other
leading international primary prevention trials [27].
As this is a pilot trial, using a questionnaire based on
Castro-Rodriguez and colleagues [18], we estimate that
using a level of 0.05 (two-tailed) and power of 80% will
require a sample size of 40 to detect a statistically signifi-
cant difference in the mean MD score of the interven-
tion group, from baseline, in the order of 3 units.Statistical analysis plan
Data analysis, using the following analysis plan, will be
blind to the allocation arm.
Descriptive analysis
For each treatment arm we will describe the participant
age (mean and standard deviation), birth weight, gender
of baby, number of previous children, the eligibility
qualifying criteria, and socioeconomic factors.
Recruitment and retention
Recruitment rate will be calculated as the proportion of
women invited to take part compared with the number
of women: responding to the invitation; meeting the
eligibility criteria; and recruited into the trial.
The retention rate will be calculated as the proportion
of women starting the study to those completing to
24 weeks post recruitment.
Mediterranean diet score
Analysis of covariance, adjusting for baseline MD score and
using a significance level of 5%, will be used to compare the
mean change in MD score from baseline to 12 and
24 weeks between the two groups. As this is a pilot study
with a small sample size we will only be able to explore
any indications of sustained adherence to the MD.
Qualitative data analysis
Recorded, end-of-trial telephone interviews with a sample
of participants will be transcribed verbatim and analysed
for key emerging themes, using a thematic content
analysis [28].
Discussion
The development of this trial has followed the UK
Medical Research Council’s framework for developing and
evaluating complex interventions [29]. In the development
phase, knowledge was used to formulate theory that
informed a systematic review and meta-analysis [12]. The
potential intervention was therefore modelled (that is, its
process and outcomes). In the current stage – that is,
feasibility and piloting – this exploratory trial has been
developed to refine the practicality of the intervention
(for example, to test procedures, to estimate recruitment
and retention, to determine sample size). This may then
lead to further piloting and feasibility work, or to a large-
scale RCT.
This is an innovative pilot RCT to assess rates of recruit-
ment and retention, and adherence to a MD pattern in
the second and third trimesters of pregnancy. No RCT
has yet investigated the role of the MD on allergy. To test
the overarching hypothesis that a MD during pregnancy
will reduce the risk of allergy in newborns, testable only in
a larger RCT with follow-up of the infants born, a pilot
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the available epidemiological evidence supports a link
between a MD and the prevention of allergy, the trial in
which we are engaged is the next step in investigating a
dietary intervention. Such an intervention has the potential
to offer a brief, effective and cost-effective intervention at
a key stage in the lifespan, which may reduce the allergy
burden on individuals and on the NHS.
Reporting and dissemination
Reporting will adhere to CONSORT [30]. A final report
will be submitted to the funding body (Chief Scientist
Office). Papers will be prepared for publication in peer-
reviewed journals. Articles reporting the results will be
circulated to all collaborators.
Trial governance
In accordance with Good Clinical Practice Guidelines
[31] and NHS research governance requirements, a
Project Management Committee has been formed,
which commented on proposed changes to the protocol
and is monitoring the trial. An independent academic is
overseeing any trial steering and data-monitoring and
ethics matters that may arise.
Trial timeline
The trial started 1 May 2012. Invitations/recruitment
material sent to potential participants (pregnant women
telephoning a centralised booking system to arrange a
dating scan appointment). Participants randomised to
the intervention arm or control arm at dating scan
appointments was ongoing from June to December
2012. Start of 12-week follow-up is ongoing from
September 2012. Start of 24 week follow-up is ongoing
from December 2012. Planned trial end date is end
July 2013. Duration of trial is 15 months.
Trial status
At the time of submission, 22 participants had been
recruited. At the end of recruitment (December 2012), 30
participants had been recruited.
Abbreviations
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